Expression of ERO1L in gastric cancer and its association with patient prognosis

  • Authors:
    • Bo Zhou
    • Gongping Wang
    • Shegan Gao
    • Ye Chen
    • Canhui Jin
    • Zengfang Wang
    • Yantong Yang
    • Zhikun Ma
    • Wei Zhang
    • Xiaoshan Feng
  • View Affiliations

  • Published online on: July 11, 2017     https://doi.org/10.3892/etm.2017.4782
  • Pages: 2298-2302
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to assess the expression of endoplasmic reticulum oxidoreductin‑1‑like (ERO1L) in gastric cancer and determine its association with patient prognosis. A total of 105 patients with gastric cancer undergoing radical gastrectomy were selected for the current study. Gastric cancer tissues (the observation group) and normal gastric tissue adjacent to the carcinoma (the control group) were resected from patients. Levels of ERO1L mRNA and protein in tumor tissues and adjacent tissues were detected using reverse transcription‑quantitative polymerase chain reaction, western blotting and immunohistochemistry. Patients were divided into two groups: A positive group and negative group, according to the expression of ERO1. The expression of ERO1L in gastric cancer and its association with patient prognosis was analyzed. Levels of ERO1 mRNA and protein in gastric cancer were significantly higher than those of adjacent tissues (P<0.05). Immunohistochemical analysis demonstrated that there were 22 patients exhibiting negative expression of ERO1L and 83 patients exhibiting positive expression of ERO1L. The cumulative recurrence rates over 3 years in patients with positive expression of ERO1L were significantly higher than in patients with negative expression of ERO1L (P<0.05); the cumulative survival rates over 3 years in patients with positive expression of ERO1L were significantly lower than those of patients with negative expression of ERO1L (P<0.05). Thus, the current study determined that ERO1L was highly expressed in gastric cancer tissue. The high expression of ERO1L was associated with adverse prognoses in patients with gastric cancer. ERO1L may therefore be a therapeutic target for the prevention of gastric cancer.

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou B, Wang G, Gao S, Chen Y, Jin C, Wang Z, Yang Y, Ma Z, Zhang W, Feng X, Feng X, et al: Expression of ERO1L in gastric cancer and its association with patient prognosis. Exp Ther Med 14: 2298-2302, 2017
APA
Zhou, B., Wang, G., Gao, S., Chen, Y., Jin, C., Wang, Z. ... Feng, X. (2017). Expression of ERO1L in gastric cancer and its association with patient prognosis. Experimental and Therapeutic Medicine, 14, 2298-2302. https://doi.org/10.3892/etm.2017.4782
MLA
Zhou, B., Wang, G., Gao, S., Chen, Y., Jin, C., Wang, Z., Yang, Y., Ma, Z., Zhang, W., Feng, X."Expression of ERO1L in gastric cancer and its association with patient prognosis". Experimental and Therapeutic Medicine 14.3 (2017): 2298-2302.
Chicago
Zhou, B., Wang, G., Gao, S., Chen, Y., Jin, C., Wang, Z., Yang, Y., Ma, Z., Zhang, W., Feng, X."Expression of ERO1L in gastric cancer and its association with patient prognosis". Experimental and Therapeutic Medicine 14, no. 3 (2017): 2298-2302. https://doi.org/10.3892/etm.2017.4782